Loading…
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Samoilova, Olga, Novak, Jan, Ben-Yehuda, Dina, Strugov, Vladimir, Gill, Devinder, Gribben, John G, Hsu, Emily, Lih, Chih-Jian, Zhou, Cathy, Clow, Fong, James, Danelle F, Styles, Lori, Flinn, Ian W
Published in The lancet oncology (01.01.2019)
Published in The lancet oncology (01.01.2019)
Get full text
Journal Article
Loading…
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.
Published in Blood (26.04.2018)
Published in Blood (26.04.2018)
Get full text
Journal Article
Loading…
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Novak, Jan, Strugov, Vladimir, Gill, Devinder, Gribben, John G., Kwei, Kevin, Dai, Sandra, Hsu, Emily, Dean, James P., Flinn, Ian W.
Published in Haematologica (Roma) (01.09.2022)
Published in Haematologica (Roma) (01.09.2022)
Get full text
Journal Article
Loading…
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
Published in Journal of clinical oncology (10.05.2019)
Published in Journal of clinical oncology (10.05.2019)
Get full text
Journal Article
Loading…
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.
Published in Blood (10.08.2017)
Published in Blood (10.08.2017)
Get full text
Journal Article
Loading…
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, Stilgenbauer, Stephan
Published in Blood (06.12.2018)
Published in Blood (06.12.2018)
Get full text
Journal Article
Loading…
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Tam, Constantine S, Brown, Jennifer R, Kahl, Brad S, Ghia, Paolo, Giannopoulos, Krzysztof, Jurczak, Wojciech, Šimkovič, Martin, Shadman, Mazyar, Österborg, Anders, Laurenti, Luca, Walker, Patricia, Opat, Stephen, Chan, Henry, Ciepluch, Hanna, Greil, Richard, Tani, Monica, Trněný, Marek, Brander, Danielle M, Flinn, Ian W, Grosicki, Sebastian, Verner, Emma, Tedeschi, Alessandra, Li, Jianyong, Tian, Tian, Zhou, Lei, Marimpietri, Carol, Paik, Jason C, Cohen, Aileen, Huang, Jane, Robak, Tadeusz, Hillmen, Peter
Published in The lancet oncology (01.08.2022)
Published in The lancet oncology (01.08.2022)
Get full text
Journal Article
Loading…
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Flinn, Ian W., van der Jagt, Richard, Kahl, Brad S., Wood, Peter, Hawkins, Tim E., MacDonald, David, Hertzberg, Mark, Kwan, Yiu-Lam, Simpson, David, Craig, Michael, Kolibaba, Kathryn, Issa, Samar, Clementi, Regina, Hallman, Doreen M., Munteanu, Mihaela, Chen, Ling, Burke, John M.
Published in Blood (08.05.2014)
Published in Blood (08.05.2014)
Get full text
Journal Article
Loading…
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, Hagop M, Hochhaus, Andreas, Saglio, Giuseppe, Souza, Carmino De, Flinn, Ian W, Stenke, Leif, Goh, Yeow-Tee, Rosti, Gianantonio, Nakamae, Hirohisa, Gallagher, Neil J, Hoenekopp, Albert, Blakesley, Rick E, Larson, Richard A, Hughes, Timothy P
Published in The lancet oncology (01.09.2011)
Published in The lancet oncology (01.09.2011)
Get full text
Journal Article
Loading…
The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival
Danilov, Alexey V., Flinn, Ian W., Davids, Matthew S., Gregory, Beth, Bentur, Ohad, Sidransky, David, Brown, Jennifer R.
Published in Haematologica (Roma) (01.10.2024)
Published in Haematologica (Roma) (01.10.2024)
Get full text
Journal Article
Loading…
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan F, Burke, John M, Zafar, Syed F, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Rao, Subramanya S, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Manda, Sudhir, Chen, Dih-Yih, By, Kunthel, Xu, Linlin, Liu, Ye, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, Huang, Jane, Sharman, Jeff P
Published in The Lancet. Haematology (01.01.2023)
Published in The Lancet. Haematology (01.01.2023)
Get more information
Journal Article
Loading…
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
Woyach, Jennifer A., Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C.
Published in Blood (04.12.2014)
Published in Blood (04.12.2014)
Get full text
Journal Article
Loading…
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jones, Jeffrey A, Robak, Tadeusz, Brown, Jennifer R, Awan, Farrukh T, Badoux, Xavier, Coutre, Steven, Loscertales, Javier, Taylor, Kerry, Vandenberghe, Elisabeth, Wach, Malgorzata, Wagner-Johnston, Nina, Ysebaert, Loic, Dreiling, Lyndah, Dubowy, Ronald, Xing, Guan, Flinn, Ian W, Owen, Carolyn
Published in The Lancet. Haematology (01.03.2017)
Published in The Lancet. Haematology (01.03.2017)
Get more information
Journal Article
Loading…
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Salles, Gilles, Schuster, Stephen J., de Vos, Sven, Wagner-Johnston, Nina D., Viardot, Andreas, Blum, Kristie A., Flowers, Christopher R., Jurczak, Wojciech J., Flinn, Ian W., Kahl, Brad S., Martin, Peter, Kim, Yeonhee, Shreay, Sanatan, Will, Matthias, Sorensen, Bess, Breuleux, Madlaina, Zinzani, Pier Luigi, Gopal, Ajay K.
Published in Haematologica (Roma) (01.04.2017)
Published in Haematologica (Roma) (01.04.2017)
Get full text
Journal Article
Loading…
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Berdeja, J. G., Hart, L. L., Mace, J. R., Arrowsmith, E. R., Essell, J. H., Owera, R. S., Hainsworth, J. D., Flinn, I. W.
Published in Haematologica (Roma) (01.05.2015)
Published in Haematologica (Roma) (01.05.2015)
Get full text
Journal Article
Loading…
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Xu, Linlin, Shadman, Mazyar, Flinn, Ian W., Levy, Moshe Y., Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte A., Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul D., Crescenzo, Rocco, By, Kunthel, Cohen, Aileen, Chen, Dih-Yih, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P., Ramakrishnan, Vanitha
Published in Haematologica (Roma) (01.07.2024)
Published in Haematologica (Roma) (01.07.2024)
Get full text
Journal Article
Loading…
Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997
Flinn, Ian W., Neuberg, Donna S., Grever, Michael R., Dewald, Gordon W., Bennett, John M., Paietta, Elisabeth M., Hussein, Mohamad A., Appelbaum, Frederick R., Larson, Richard A., Moore, Dennis F., Tallman, Martin S.
Published in Journal of clinical oncology (01.03.2007)
Published in Journal of clinical oncology (01.03.2007)
Get full text
Journal Article
Loading…
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
Grever, Michael R., Lucas, David M., Dewald, Gordon W., Neuberg, Donna S., Reed, John C., Kitada, Shinichi, Flinn, Ian W., Tallman, Martin S., Appelbaum, Frederick R., Larson, Richard A., Paietta, Elisabeth, Jelinek, Diane F., Gribben, John G., Byrd, John C.
Published in Journal of clinical oncology (01.03.2007)
Published in Journal of clinical oncology (01.03.2007)
Get full text
Journal Article
Loading…
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
Byrd, John C., Pagel, John M., Awan, Farrukh T., Forero, Andres, Flinn, Ian W., Deauna-Limayo, Delva P., Spurgeon, Stephen E., Andritsos, Leslie A., Gopal, Ajay K., Leonard, John P., Eisenfeld, Amy J., Bannink, Jeannette E., Stromatt, Scott C., Furman, Richard R.
Published in Blood (27.02.2014)
Published in Blood (27.02.2014)
Get full text
Journal Article
Loading…
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Tedeschi, Alessandra, Greil, Richard, Demirkan, Fatih, Robak, Tadeusz, Moreno, Carol, Barr, Paul M., Anz, Bertrand, Simpson, David, Gaidano, Gianluca, Bairey, Osnat, Stevens, Don, Gill, Devinder, Flinn, Ian W., Kipps, Thomas J., Burger, Jan A., Lin, Jennifer, Webb, Thomas, Fedorov, Viktor, Styles, Lori, Gribben, John G.
Published in Haematologica (Roma) (01.04.2020)
Published in Haematologica (Roma) (01.04.2020)
Get full text
Journal Article